LXRX (STOCKS)
Lexicon Pharmaceuticals, Inc.
$2.330000
-0.020000 (-0.85%)
Prev close: $2.350000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Michael Exton
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,050.13M
- Employees
- 103
- P/E (TTM)
- -15.28
- P/B (TTM)
- 5.99
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
5
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.07 | $-0.05 | -0.0188 | -36.72% |
|
Mar 2026 (Q1)
|
$0.00 | $-0.04 | +0.0351 | +100.00% |
|
Dec 2025 (Q4)
|
$-0.04 | $-0.07 | +0.0304 | +43.18% |
|
Sep 2025 (Q3)
|
$-0.04 | $-0.07 | +0.0273 | +40.56% |
Financial Statements
| Revenues | $41.47M |
| Benefits Costs and Expenses | $95.97M |
| Cost Of Revenue | $358.00K |
| Costs And Expenses | $95.97M |
| Gross Profit | $41.11M |
| Operating Expenses | $95.61M |
| Selling, General, and Administrative Expenses | $35.34M |
| Research and Development | $60.27M |
| Operating Income/Loss | -$54.50M |
| Income/Loss From Continuing Operations After Tax | -$61.12M |
| Income/Loss From Continuing Operations Before Tax | -$54.50M |
| Net Income/Loss | -$61.12M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$61.12M |
| Net Income/Loss Available To Common Stockholders, Basic | -$61.12M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.16 |
| Diluted Earnings Per Share | -$0.16 |
| Basic Average Shares | 782,575,000 |
| Diluted Average Shares | 782,575,000 |
| Assets | $250.06M |
| Current Assets | $196.58M |
| Inventory | $1.20M |
| Other Current Assets | $195.38M |
| Noncurrent Assets | $53.48M |
| Fixed Assets | $1.65M |
| Other Non-current Assets | $51.83M |
| Liabilities | $75.54M |
| Current Liabilities | $14.71M |
| Accounts Payable | $2.34M |
| Wages | $3.90M |
| Other Current Liabilities | $8.47M |
| Noncurrent Liabilities | $60.83M |
| Equity | $174.53M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $174.53M |
| Liabilities And Equity | $250.06M |
| Net Cash Flow From Operating Activities | -$64.99M |
| Net Cash Flow From Operating Activities, Continuing | -$64.99M |
| Net Cash Flow From Investing Activities | -$29.77M |
| Net Cash Flow From Investing Activities, Continuing | -$29.77M |
| Net Cash Flow From Financing Activities | $85.32M |
| Net Cash Flow From Financing Activities, Continuing | $85.32M |
| Net Cash Flow | -$9.44M |
| Net Cash Flow, Continuing | -$9.44M |
| Comprehensive Income/Loss | -$61.31M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$61.31M |
| Other Comprehensive Income/Loss | -$61.31M |